Although the domestic "Regenerative Medicine Act" continues to be blocked, according to Xunlian Biotechnology's "Report to Shareholders", the company currently has more than 60 cell therapy projects in progress, covering neurology, orthopedics, rheumatology and immunology, plastic surgery 7 major fields including surgery, dermatology, medical aesthetics, and tumor immune cell therapy.
In addition, they have applied the cell therapy and regenerative medicine experience of the human "Special Control Law" to pet cell therapy in parallel, and have cooperated with major veterinary medical research institutions to simultaneously carry out a number of field trials and academic research on animal cell therapy, including Degenerative arthritis and spinal injuries in large animals, tendon and ligament injuries in horses, chronic renal failure in cats, etc.
Laying out the next ten years:
Looking forward to the future, Cai Zhengxian proposed four strategic indonesia telegram directions, hoping to gain an advantage in the competitive market.
Using AI to acquire and retain customers is so easy! Infobip helps brand customers reduce revenue costs and implement precise marketing
First, start the layout of the group's "Xunlian Cell Intelligent Medicine" and become the third listed OTC company in the group, so as to seize the vast business opportunities of regenerative medical preparations.
Second, Xunlian will expand its PIC/S GMP (a globally recognized international standard) regenerative medical preparations factory this year. Cai Zhengxian added that they will focus on exporting "exosome"-related preparations and set their sights on overseas markets such as Japan, South Korea, Hong Kong, Indonesia, Malaysia, and the United States. "The reason is that the market value of 'exosomes' will reach US$163.5 billion in 2021, with a compound annual growth rate of 31.5%, and it is easy to transport and apply locally (such as skin care, hair growth, etc.), and it is the most potential in cell therapy Export products internationally.
exosome market
Xunlian Biotech will expand the application of exosomes from detection, diagnosis, treatment to new drug development.
Picture/Provided by Xunlian Biotechnology
Third, its subsidiary "Xunlian Gene Digital" will continue to develop precision health, next-generation gene sequencing (NGS) and other genetic testing, aiming to achieve a market penetration rate of 90%.
Fourth, in addition to focusing on the biotech and medical industry, Xunlian will invest in smart research and development technology, including laboratory data management, scientific simulation, cross-border assistance with new crown traditional Chinese medicine, AI process optimization, 5G materials, electric vehicle batteries, etc., with the goal of expanding revenue .
- Board index
- All times are UTC
- Delete cookies
- Contact us